Drug Approval | September 06, 2021
DGCI approves Hetero’s Tocilizumab
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
The segment delivered strong sales growth of 20% YoY
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
The submission to the US FDA has been initiated and they intend to file these data with the European Medicines Agency and other regulatory bodies in the coming weeks
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
Subscribe To Our Newsletter & Stay Updated
